Monoclonal Antibody Collaboration and Licensing Deals 2016-2024


Monoclonal Antibody Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2024

Publication date
May 2024
Number of pages
Product type
Research report
Available formats
PDF document
Report edition

Monoclonal Antibody Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the monoclonal antibody deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of monoclonal antibody deals from 2016 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 974 monoclonal antibody deals announced since 2016 including financial terms where available including links to online deal records of actual monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of monoclonal antibody dealmaking. 

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in monoclonal antibody dealmaking since 2016.

Chapter 3 provides an overview of the leading monoclonal antibody deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of monoclonal antibody deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of monoclonal antibody deals signed and announced since Jan 2016, where a contract document is available in the public domain. 

Chapter 6 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since Jan 2016. The chapter is organized by specific monoclonal antibody technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in monoclonal antibody deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Monoclonal Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:

•    Understand deal trends since 2016
•    Browse monoclonal antibody collaboration and licensing deals
•    Benchmark analysis – identify market value of transactions
•    Financials terms - upfront, milestone, royalties
•    Directory of deals by company A-Z, deal type and therapy area
•    Leading deals by value
•    Most active dealmakers
•    Identify assets and deal terms for each transaction
•    Access contract documents - insights into deal structures
•    Due diligence - assess suitability of your proposed deal terms for partner companies
•    Save hundreds of hours of research time

Report scope

Monoclonal Antibody Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of monoclonal antibody trends and structure of deals entered into by leading biopharma companies worldwide.

Monoclonal Antibody Collaboration and Licensing Deals includes:
•    Trends in monoclonal antibody dealmaking in the biopharma industry
•    Directory of monoclonal antibody deal records covering pharmaceutical and biotechnology
•    The leading monoclonal antibody deals by value
•    Most active monoclonal antibody licensing dealmakers

Monoclonal Antibody Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

•    What are the precise rights granted or optioned?
•    What is actually granted by the agreement to the partner company?
•    What exclusivity is granted?
•    What is the payment structure for the deal?
•    How are sales and payments audited?
•    What is the deal term?
•    How are the key terms of the agreement defined?
•    How are IPRs handled and owned?
•    Who is responsible for commercialization?
•    Who is responsible for development, supply, and manufacture?
•    How is confidentiality and publication managed?
•    How are disputes to be resolved?
•    Under what conditions can the deal be terminated?
•    What happens when there is a change of ownership?
•    What sublicensing and subcontracting provisions have been agreed?
•    Which boilerplate clauses does the company insist upon?
•    Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
•    Which jurisdiction does the company insist upon for agreement law?

Monoclonal Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:

•    Understand deal trends since 2016
•    Browse monoclonal antibody collaboration and licensing deals
•    Benchmark analysis – identify market value of transactions
•    Financials terms - upfront, milestone, royalties
•    Directory of deals by company A-Z, deal type and therapy area
•    Leading deals by value
•    Most active dealmakers
•    Identify assets and deal terms for each transaction
•    Access contract documents - insights into deal structures
•    Due diligence - assess suitability of your proposed deal terms for partner companies
•    Save hundreds of hours of research time

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in monoclonal antibody dealmaking
2.1. Introduction
2.2. Monoclonal antibody deals over the years
2.3. Most active monoclonal antibody dealmakers
2.4. Monoclonal antibody deals by deal type
2.5. Monoclonal antibody deals by therapy area
2.6. Monoclonal antibody deals by industry sector
2.7. Deal terms for monoclonal antibody deals
2.7.1 Monoclonal antibody deals headline values
2.7.2 Monoclonal antibody deal upfront payments
2.7.3 Monoclonal antibody deal milestone payments
2.7.4 Monoclonal antibody royalty rates

Chapter 3 – Leading monoclonal antibody deals
3.1. Introduction
3.2. Top monoclonal antibody deals by value

Chapter 4 – Most active monoclonal antibody dealmakers
4.1. Introduction
4.2. Most active monoclonal antibody dealmakers
4.3. Most active monoclonal antibody deals company profiles

Chapter 5 – Monoclonal antibody contracts dealmaking directory
5.1. Introduction
5.2. Monoclonal antibody contracts dealmaking directory

Chapter 6 – Monoclonal antibody dealmaking by technology type

Deal directory

Deal directory – Monoclonal antibody deals by company A-Z
Deal directory – Monoclonal antibody deals by deal type
Deal directory – Monoclonal antibody deals by therapy area

Deal type definitions

About Biopharma Research Ltd  
Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Monoclonal antibody deals since 2016
Figure 2: Active monoclonal antibody dealmaking activity – 2016 - 2024
Figure 3: Monoclonal antibody deals by deal type since 2016
Figure 4: Monoclonal antibody deals by therapy area since 2016
Figure 5: Monoclonal antibody deals by industry sector since 2016
Figure 6: Monoclonal antibody deals with a headline value
Figure 7: Monoclonal antibody deals with an upfront value
Figure 8: Monoclonal antibody deals with a milestone value
Figure 9: Monoclonal antibody deals with a royalty rate value
Figure 10: Top monoclonal antibody deals by value since 2016
Figure 11: Most active monoclonal antibody dealmakers 2016 - 2024
Figure 12: Monoclonal antibody deals by technology type since 2016

Pricing options

  • $3,995: single-user (encrypted file - one user/device)
  • $5,995: multi-user (encrypted file - up to 5 users/devices)
  • $9,995: company (unencrypted file)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

1ST Biotherapeutics, 3D Medicines, 3rd People’s Hospital of Shenzhen, 3SBio, 4D Pharma, 9 Meters Biopharma, A*STAR Agency for Science, Technology and Research, A*STAR Bioprocessing Technology Institute, Abbvie, Abcam, AbCellera Biologics, AbClon, Abdul Latif Jameel Health, ABL Bio, Ablexis, Ablynx, Abmuno Therapeutics, Aboundbio, Abpro, Ab Studio, Abveris, Abzena, Accord Healthcare, AcedrA BioPharmaceuticals, Acerta Pharma, AchilleS Vaccines, Acticor Biotech, Adagene, Adaptimmune, Adaptive Biotechnologies, Adimab, Adlai Nortye, Aduro BioTech, Advanced BioScience Laboratories, Advanz Pharma, Advaxis, Aegis Life, Aeglea BioTherapeutics, Aevi Genomic Medicine, AffaMed Therapeutics, Affimed Therapeutics, AGC Biologics, Agenus Bio, Agilent Technologies, AgomAb Therapeutics, AimedBio, AIM ImmunoTech, Aimmune Therapeutics, Ajinomoto, Akeso Biopharma, Alder Biopharmaceuticals, Alector, Alexion Pharmaceuticals, Alfasigma, AlivaMab Discovery Services, Allergan, Alligator Bioscience, Allinaire Therapeutic, Alloy Therapeutics, Almac Group, Almirall, Alphamab Biopharmaceuticals, Alpine Immune Sciences, Alvogen, Alvotech, ALX Oncology, Alzheimer's Drug Discovery Foundation, Ambrx, Amgen, Amneal Pharmaceuticals, Amolyt Pharma, Amplyx Pharmaceuticals, Angios, Ankyra Therapeutics, Antengene, Antidote Therapeutics, Antigen Express, Aperion Biologics, Apexigen, Apollo Therapeutics, Applied BioMath, APRINOIA Therapeutics, Aptevo Therapeutics, Arch Oncology, Arcus Biosciences, argenx, Aridis Pharmaceuticals, Arovella Therapeutics, Array Biopharma, Arsanis Biosciences, Ascentage Pharma, Asher Biotherapeutics, Asieris MediTech, Aslan Pharma, Astellas Pharma, Astex Pharmaceuticals, AstraZeneca, Astria Therapeutics, Atara Biotherapeutics, Athenex, Atlab Pharma, Atlante Biotech, Atlas Antibodies, Atreca, ATUM, Augmenta, Avalo Therapeutics, AvantGen, Avantor, AVEO Oncology, Avid Bioservices, Avidity Biosciences, Axantia, Back-A-Line, Banner Alzheimer's Institute, Basilea Pharmaceutica, Bausch & Lomb, Bavarian Nordic, Baxalta, Bayer, BB100, Beckman Coulter, BeiGene, Beijing InnoCare Pharma, Beijing Tianshi Tongda Pharmaceuticals Technology, BerGenBio, Berkeley Lights, Betta Pharmaceuticals, Bill and Melinda Gates Foundation, Bio-Manguinhos/Fiocruz, Bio-Thera Solutions, BioArctic AB, BioAtla, BioCity Biopharma, Biocon, Biocytogen, Biodesix, Bioeq IP, Biogen, BioInvent, BiolineRX, BioMarker Strategies, Biomedical Advanced Research and Development Authority, Biomm, Biomunex Pharmaceuticals, Bioncotech Therapeutics, Biond Biologics, Bionoveo, BioNTech, BioRap Technologies, BiosanaPharma, Biosion, Biothera Pharmaceuticals, Biotheus, Biotools, BioXcel, BJ Bioscience, Blackstone, Bluebird Bio, BlueJay Therapeutics, Boehringer Ingelheim, Bolt Biotherapeutics, Boston Immune Technologies and Therapeutics, Bpifrance, BridgeBio Pharma, Brigham and Women's Hospital, Bright Peak Therapeutics, Brii Biosciences, Bristol-Myers Squibb, C-Bridge Capital, Caelum Biosciences, California Institute for Regenerative Medicine, Calithera Biosciences, Calypso Biotech, CanariaBio, Cancer Focus Fund, Cancer Prevention and Research Institute of Texas, Cancer Research UK, Cancer Science Institute of Singapore, CanCure, Candel Therapeutics, Cantargia, Care Access Research, Caris Life Sciences, CARsgen, Cartexell, CASI Pharmaceuticals, CBT Pharmaceuticals, Cedars-Sinai Medical Center, Celgene, Celiac Disease Foundation, Cellectis, Celltrion, Celsius Therapeutics, Celularity, Cend Therapeutics, Centre for Drug Research and Development (CDRD), Cessation Therapeutics, CG Oncology, Champions Oncology, Checkmate Pharmaceuticals, Chi-Med, Chiesi Farmaceutici, Chime Biologics, China Resources Pharmaceutical Commercial Group International Trading, Chiome Bioscience, Chugai Pharmaceutical, Cilag AG, Cipla, Circio, City of Hope Comprehensive Cancer Center, Clinical Trial and Consulting Services, Clinica Universidad Navarra, Clovis Oncology, CMAB Biopharma, CMC Biologics, Coherus Biosciences, Cold Genesys, Columbia University, Compass Therapeutics, Complement Pharma, Compugen, Convergent Therapeutics, Corvidia Therapeutics, Corvus Pharmaceuticals, Covalab, Creative Biolabs, Crescendo Biologics, Cromos Pharma, Crown Bioscience, CR Pharma, CSL, CSPC Pharmaceutical Group, CStone Pharmaceuticals, Cue Biopharma, Cullinan Oncology, Curant Health, Curative Biotechnology, Cure Duchenne, CureVac, Curia, Curis, Cytea Bio, Cytodyn, Cytovation, Daiichi Sankyo, Debiopharm, Defense Advanced Research Projects Agency, Denali Therapeutics, Department of Defense, Department of Health and Human Services, Dermira, Diaprost, Disc Medicine, Distributed Bio, Dong-A ST, Dr. Reddy's Laboratories, Duke University, Dyadic International, E25Bio, EA Pharma, eFFECTOR Therapeutics, EirGenix, Eisai, Elanco, Elektrofi, Elevar Therapeutics, Elevation Oncology, Eleven Biotherapeutics, Elicio Therapeutics, Eli Lilly, ElsaLys Biotech, Emergent BioSolutions, Enlivex, Enthera, Entos Pharmaceuticals, Enumeral Biomedical, Enzene Biosciences, Enzolytics, EpiThany, EQRx, Equillium, Erasca, Erasmus University Medical Center, EsoCap, Essex Bio-Technology, Eucure Biopharma, Eurofarma, European Union Regional Development Fund, EUSA Pharma, Eutilex, Evaxion Biotech, Everest Medicines, Eversana, Evopoint Biosciences, Evotec, Excellmab, Exelixis, F-Star Therapeutics, FairJourney Biologics, FatiAbGen, Ferring Pharmaceuticals, Five Prime Therapeutics, FLX Bio, Food and Drug Administration (FDA), Formosa Pharmaceuticals, Forty Seven, Fosun Kite Biotechnology, Fosun Pharmaceutical, Foundery Innovations, Fred Hutchinson Cancer Research Center, French National Blood Service, Fresenius Kabi Pharmaceuticals, Frontage Clinical Services, Fuhong Hanlin, Fujifilm Kyowa Kirin Biologics, Fuji Pharma, Fujirebio Diagnostics, Fusion Pharmaceuticals, Galapagos, Galaxy Biotech, Galderma, Galecto, GBI BioManufacturing, Genagon Therapeutics, Genentech, Generation Biotech, Genexine, GenFleet Therapeutics, Genmab, Gennao Bio, Genome and Company, Genor Biopharma, Genprex, GenScript Biotech, GenScript ProBio, Georgetown University, Gilead Sciences, Glenmark Pharmaceuticals, Global Blood Therapeutics, Glycotope Biotechnology, Glythera, Goldfinch Bio, Gossamer Bio, GO Therapeutics, Gradalis, Gritstone Bio, GSK, GTP Technology, H-Immune, H3 Biomedicine, Hadasit Bioholdings, Halozyme Therapeutics, HanAll Pharmaceuticals, Harbour Antibodies, Harbour Biomed, Heidelberg Pharma, Henlius Biotech, HiberCell, HIBio, HiFiBio, Highlight Therapeutics, High Line Bio, Hikma Pharmaceuticals, Hisun BioRay, Hoffmann La Roche, Hookipa Pharma, Hope Medicine, Horizon Discovery, Horizon Therapeutics, Huadong Medicine, Hualan Genetic, Humanigen, Hummingbird Bioscience, Hutchison MediPharma, Huyabio International, Hypospray Pharma, I-mab, iBio, Icahn School of Medicine at Mount Sinai, IcanoMAB, Ichnos Sciences, Ichor Medical Systems, IDBiologics, iDD Biotech, IDEAYA Biosciences, Igyxos, ImCheck Therapeutics, ImClone Systems, IMIDomics, Immatics Biotechnologies, Immix Biopharma, Immune-Onc Therapeutics, ImmuneCyte Life Sciences, ImmuneOncia Therapeutics, Immune Pharmaceuticals, ImmuNext, Immunicum, Immunitas Therapeutics, ImmunoChina Pharmaceuticals, Immunocore, ImmunoGen, Immunome, Immunomedics, Immunomic Therapeutics, ImmunoPrecise Antibodies, Immunovaccine, Immutep, IMPACT Therapeutics, Imugene, IMV, Incyte, InDevR, Indiana University, Indian Institute of Science Education and Research, Infex Therapeutics, Infinity Pharmaceuticals, InflamaCORE, InflaRx, Inhalon Biopharma, Initium Therapeutics, Innate Pharma, Innovate UK, Innovent Biologics, Inovio, Inovio Pharmaceuticals, InSilicoTrials, Inspirna, Institut Bergonie, Institute for Basic Science, Institut Pasteur, Intas Pharmaceuticals, Integral Molecular, INTELLiSTEM, Intensity Therapeutics, International Consortium on Anti-Virals, IntoCell, Intract Pharma, Invenra, Invetx, InxMed, IO Biotech, Ionova, IONTAS, Ipsen, IRBM, ISA Pharmaceuticals, Israel Institute for Biological Research, Italian Association for the Study of Pancreas, iTeos Therapeutics, Izana Bioscience, Jacobio Pharmaceuticals, Janssen Biotech, Janssen Pharmaceuticals, Janssen Research & Development, Janssen Sciences, Jasper Therapeutics, Jazz Pharmaceuticals, JHL Biotech, Jiangsu Alphamab, Jiangsu Hansoh Pharmaceutical, Jiangsu Hengrui Medicine, Jiangsu Hengrui Pharmaceuticals, Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Innovation, Jounce Therapeutics, Juno Therapeutics, Junshi Biosciences, Just Biotherapeutics, Juvenile Diabetes Research Foundation, KAHR Medical, Kalbe Genexine Biologics, KangaBio, KBI BioPharma, KBio, Kelun-Biotech Biopharmaceutical, Kennedy Institute of Rheumatology, Kiadis Pharma, Kindred Bio, Kineta, Kiniksa Pharmaceuticals, Kintor, Kite Pharma, Kleo Pharmaceuticals, Kodiak Sciences, Kolltan Pharmaceuticals, KPM Tech, Kymab, Kyowa Hakko Kirin, Kyttaro, Laboratoires Thea, Laekna, LakePharma, Lassen Therapeutics, Lava Therapeutics, Leap Therapeutics, Lee's Pharmaceutical, Leica Biosystems, LEO Pharma, Les Laboratoires Servier, Leukemia & Lymphoma Society, LG Life Sciences, LifeArc, LifeMax Laboratories, Ligand Pharmaceuticals, Linnaeus Therapeutics, Liverpool School of Tropical Medicine, Livzon Mabpharm, Lobesity Pharma, Lonza, Lumos Pharma, Lunit, Lupagen, Lupus Therapeutics, Lyvgen Biopharma, MAB Discovery, MabQuest, MAbSilico, mAbsolve, Mabspace Bioscience, mAbXience, Mabylon, Macrogenics, Magenta Therapeutics, MAIA Biotechnology, Manhattan BioSolutions, Mapp Biopharmaceutical, Massachusetts General Hospital, Matrix Medical Network, Mayo Clinic, McLean Hospital, MD Anderson Cancer Center, Medgenics, Medical Research Council, Medicenna Therapeutics, Medimabs, MedImmune, Mediolanum, Medison Pharma, Meiji Seika, Memorial Sloan Kettering Cancer Center, Merck and Co, Merck KGaA, Merck Sharpe & Dohme, Mereo BioPharma, Merrimack Pharmaceuticals, Merus, Microbiotica, Mitra Biotech, Mitsubishi Tanabe Pharma, ModiQuest Research, Molcure, Moleculin Biotech, MolMed, Momenta Pharmaceuticals, Monopar Therapeutics, MoonLake Immunotherapeutics, MorphoSys, Morphotek, Mount Sinai Health System, MSD, MS Pharma, Mundipharma, Mustang Bio, Mylan Laboratories, Mylan Pharmaceuticals, Myriad Genetics, myTomorrows, Nanjing Leads Biolabs, Nantes University, Nanyang Technological University, Nascent Biotech, National Cancer Institute, National Center for Advancing Translational Sciences (NCATS), National Center for Tumor Diseases, National Comprehensive Cancer Network (NCCN), National Heart, Lung and Blood Institute, National Institute for Bioprocessing Research and Training, National Institute of Allergy and Infectious Diseases, National Institute on Drug Abuse (NIDA), National Institutes of Health, National University Cancer Institute, Navrogen, Nectin Therapeutics, Nektar Therapeutics, Nelum Pharma, NeoImmuneTech, Neoleukin Therapeutics, Neon Therapeutics, Neotope, NETRIS Pharma, Neuraxpharm, Neurimmune Therapeutics, Neuroblastoma and Medulloblastoma Translational Research, Newsummit Biopharma, Neximmune, Nexvet, NGM Biopharmaceuticals, NiKang Therapeutics, Nkarta Therapeutics, NKGen Biotech, NKMax America, Nona Biosciences, Nordic Society of Gynaecological Oncology, NorthStar Medical Radioisotopes, Northwestern University, Nouscom, NovalGen, NovaRock Biotherapeutics, Novartis, Novasep, Novelogics Biotechnology, Novelty Nobility, NovImmune, Novocure, Novo Nordisk, Noxopharm, Noxxon Pharma, Numab, Nykode Therapeutics, OBI Pharma, Olatec Therapeutics, Olivia Newton-John Cancer Research Institute, Ology Bioservices, Olympic Protein Technologies, Omeros, OncoC4, OncoCare Therapeutics, OncoImmune, Oncologie, Oncolytics Biotech, OncoQuest, OncoResponse, OncoSec Medical, OncoVent, OncoVerity, Oncternal Therapeutics, Oncurious, OncXerna Therapeutics, Ono Pharmaceutical, Ordaos Bio, Orient EuroPharma, OSE Immunotherapeutics, Otsuka, Oxford BioTherapeutics, Pall Corporation, Panacea Pharmaceuticals, Pandion Therapeutics, Panorama Research, Parexel Biotech, Pascal Biosciences, PDS Biotechnology, Peregrine Pharmaceuticals, Personal Genome Diagnostics, Personalis, Pfizer, Phanes Therapeutics, PharmAbcine, PharmaEssentia, Pharmapark, PhaseBio Pharmaceuticals, Pieris Pharmaceuticals, Pierre Fabre, Pionyr Immunotherapeutics, PlantForm, PlantPraxis Biotecnologia, PMV Pharma, Pneuma Respiratory, POINT Biopharma, Polpharma, Portage Biotech, Portal Instruments, Poseida Therapeutics, Precision BioSciences, Prellis Biologics, Prestige BioPharma, ProBioGen, Progenetics, Progenics Pharmaceuticals, Promega, Prothena, ProtoKinetix, Provention Bio, PT Etana Biotechnologies, PULSALYS, PureTech Health, Pyxis Oncology, Q32 Bio, QBiotics, Qiagen, Quantum Leap Health Care Collaborative, Queensland Institute of Medical Research (QIMR), Quest PharmaTech, Qurient, R-Pharm, Radboud University Nijmegen Medical Centre, Rallybio, Rani Therapeutics, RefleXion Medical, Regeneron Pharmaceuticals, Regenxbio, Regnum, Releviate Therapeutics, RemeGen, Replimune, Rexahn Pharmaceuticals, Rezolute, Ridgeback Biotherapeutics, Roche, Rockefeller University, Rocket Pharmaceuticals, Roivant Sciences, Roswell Park Cancer Institute, RQ Biotechnology, RubrYc Therapeutics, Rxilient Biotech, Rznomics, SAB Biotherapeutics, Saccharo, Saga University, Samsung Bioepis, Samsung Biologics, Samyang Biopharmaceuticals, San Diego Biomedical Research Institute, Sandoz, Sanofi, Sanofi-Aventis, Sanofi-Pasteur, Sanofi US Services, Sanyou Biopharmaceuticals, Sarah Cannon Research Institute, SATT Sud-Est, SaudiVax, Scandion Oncology, Schrodinger, SciClone Pharmaceuticals, SciNeuro Pharmaceuticals, Scripps Research Institute, Seagen, Seattle Genetics, Seismic Bio, Seismic Therapeutic, Selecxine, Selexis, SELLAS Life Sciences Group, Sensei Biotherapeutics, SERB Pharmaceuticals, Serum Institute of India, Seven and Eight Biopharmaceuticals, SevenScore Pharmaceuticals, SFJ Pharmaceuticals, Shandong Fontacea Pharmaceutical, Sharp HealthCare, Shenogen Pharma, Shenzhen Arimab Biopharmaceuticals, Shenzhen Chipscreen Biosciences, Shionogi, SHL Medical, Simcere Pharmaceuticals, Simcha Therapeutics, Simon Fraser University, Sirnaomics, Sonnet BioTherapeutics, Sorrento Therapeutics, Sosei Heptares, SOTIO, Spanish National Research Council, Specialised Therapeutics, Specialized Medical Services-oncology, SpikImm, STADA Arzneimittel, Stanford University, Strata Oncology, Sud Investments, Sun Pharmaceutical, Surface Oncology, Suzhou Connect Biopharmaceuticals, Swedish Orphan, Swedish Orphan Biovitrum, Syndax Pharmaceuticals, Syngene International, Synlogic, Syracuse University, Syros Pharmaceuticals, T-Cure Bioscience, Taiho, TaiMed, Takeda Pharmaceutical, Talem Therapeutics, Tanabe Research Laboratories, TARIS Biomedical, Tavotek Biotherapeutics, TCR2 Therapeutics, Telcon RF Pharmaceuticals, Telix Pharmaceuticals, Tempest Therapeutics, TeneoBio, Teon Therapeutics, Tesaro, Tessa Therapeutics, Tetragenetics, Teva Pharmaceutical Industries, Teva Pharmaceuticals USA, TFF Pharmaceuticals, TG Therapeutics, The International AIDS Vaccine Initiative, Theramex, Theranyx, Thermo Fisher Scientific, ThromboGenics, TILT Biotherapeutics, Tiziana Life Sciences, Tizona Therapeutics, Tmunity Therapeutics, TNAX Biopharma, TONIX Pharmaceuticals, Toregem BioPharma, Torque Therapeutics, TOT BIOPHARM, TRACON Pharmaceuticals, Transcenta, Transgene, TransThera, Tri-Institutional Therapeutics Discovery Institute, TrialSpark, Trianni, Trieza Therapeutics, Trinomab Biotech, Trio Pharmaceuticals, Triumvira Immunologics, TSB Therapeutics, Tsinghua University, Turgut Ilaclari, Twist Bioscience, UbiVac, UCB, Ultragenyx Pharmaceuticals, UnitedHealth, Universite Claude Bernard Lyon, University College London, University of Bergen, University of Birmingham, University of British Columbia, University of California, San Diego, University of California Los Angeles, University of California Riverside, University of California San Francisco, University of Florida, University of New Mexico, University of Oxford, University of Pennsylvania, University of Washington, University of Wisconsin Carbone Cancer Center (UWCCC), Upadia, Uppsala University, UroGen Pharma, US Army Medical Research and Material Command, US Army Medical Research Institute of Infectious Diseases, Utrecht University, Vaccinex, ValenzaBio, Vanderbilt University, Vaximm, Vcell Healthcare, Vect-Horus, Vedanta Biosciences, Velabs Therapeutics, Verseau Therapeutics, Vetter, Viela Bio, Vir Biotechnology, Viroclinics Biosciences, Visterra, Vitaeris, Voyager Therapeutics, Vyera Pharmaceuticals, Vyriad, Wellmarker Bio, Werewolf Therapeutics, Wilex, WindMIL Therapeutics, Wistar Institute, WuXi Biologics, Wuxi Shuangliang Biotechnology, Xbrane Bioscience, xCella Biosciences, Xencor, XERIS Pharmaceuticals, Xilio Therapeutics, Xoma, Xuanzhu Biopharma, Xyphos Biosciences, Y-Biologics, Y-mAbs Therapeutics, Yale Cancer Center, Yale University, Yas Holding, ZabBio, ZAI Laboratory, Zenas BioPharma, Zenoaq, Zenyaku Kogyo, Zhejiang Bossan Pharmaceutical, Zhejiang Hisun Pharmaceutical, Zhejiang Huahai Pharmaceutical, Zoetis, Zumutor Biologics, Zura Bio, Zydus Cadila, Zymedi, Zymeworks, ZyVersa Therapeutics

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.